Compare MOD & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOD | NBIX |
|---|---|---|
| Founded | 1916 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.1B | 13.2B |
| IPO Year | 1995 | 1996 |
| Metric | MOD | NBIX |
|---|---|---|
| Price | $243.69 | $128.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 22 |
| Target Price | ★ $223.71 | $180.91 |
| AVG Volume (30 Days) | 817.1K | ★ 1.1M |
| Earning Date | 05-19-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 12.87 | ★ 41.95 |
| EPS | 0.90 | ★ 4.67 |
| Revenue | ★ $1,352,500,000.00 | $161,626,000.00 |
| Revenue This Year | $23.05 | $24.73 |
| Revenue Next Year | $21.83 | $13.14 |
| P/E Ratio | $279.94 | ★ $27.34 |
| Revenue Growth | N/A | ★ 977.51 |
| 52 Week Low | $77.29 | $105.16 |
| 52 Week High | $260.01 | $160.18 |
| Indicator | MOD | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 56.18 | 44.69 |
| Support Level | $232.14 | $124.62 |
| Resistance Level | $260.01 | $135.88 |
| Average True Range (ATR) | 13.46 | 3.55 |
| MACD | -0.10 | -0.26 |
| Stochastic Oscillator | 52.96 | 25.15 |
Modine Manufacturing Co provides thermal management solutions to diversified markets and customers. The company provides engineered heat transfer systems and heat transfer components for use in on- and off-highway original equipment manufacturer (OEM) vehicular applications in the United States. It offers powertrain cooling products, such as engine cooling assemblies, radiators, condensers, and charge air coolers; auxiliary cooling products, including power steering and transmission oil coolers. Its operating segments include Climate Solutions and Performance Technologies.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.